It is thus crucial to gain a deeper understanding of SCAP/SREBP regulation in MASLD, which may open avenues for novel therapeutic drug designs targeting the SCAP/SREBP axis for treating fatty liver and hypertriglyceridemia [8]. Here, SCAP is linked to metabolic dysfunction-associated steatotic liver disease.